Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15980356 | 0.76 | MAPT (0.47) | CYP1A2CYP2A6UHRF1 | |
| SCHEMBL14577596 | 0.69 | NQO2 (0.39) | CYP1A2CYP2A6 | |
| SCHEMBL15935260 | 0.69 | HASPIN (0.31) | — | |
| SCHEMBL15910805 | 0.68 | KDM4E (0.61) | — | |
| SCHEMBL13684173 | 0.66 | SLC6A2 (0.36) | CYP1A2 | |
| SCHEMBL21214991 | 0.66 | LATS1 (0.33) | — | |
| SCHEMBL22790582 | 0.64 | SCN10A (0.38) | — | |
| SCHEMBL18266963 | 0.63 | CYP1A2 (0.67) | CYP1A2CYP2A6UHRF1 | |
| SCHEMBL22790581 | 0.63 | — | — | |
| SCHEMBL12965817 | 0.62 | CYP1A2 (0.46) | CYP1A2CYP2A6UHRF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | HSD17B13, HSD17B3, HSD17B1 | CYP1A2 48/4885CYP2A6 66/4885UHRF1 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.